专利检索 ipc:C07D413/10 第 1 页

1.

发明公开
NOVEL KINASE MODULATORS 审中-公开

公开(公告)号：US20240360095A1

公开(公告)日：2024-10-31

申请号：US18508085

申请日：2023-11-13

申请人： RHIZEN PHARMACEUTICALS AG

发明人： MEYYAPPAN MUTHUPPALANIAPPAN , Srikant VISWANADHA , Govindarajulu BABU , Swaroop K. VAKKALANKA

IPC分类号： C07D311/36 , A61K31/352 , A61K31/4178 , A61K31/4184 , A61K31/437 , A61K31/519 , A61K31/52 , A61K31/522 , A61K31/5377 , A61K45/06 , C07D405/06 , C07D413/10 , C07D413/14 , C07D471/04 , C07D473/08 , C07D473/34 , C07D473/38 , C07D473/40 , C07D487/04

CPC分类号： C07D311/36 , A61K31/352 , A61K31/4178 , A61K31/4184 , A61K31/437 , A61K31/519 , A61K31/52 , A61K31/522 , A61K31/5377 , A61K45/06 , C07D405/06 , C07D413/10 , C07D413/14 , C07D471/04 , C07D473/08 , C07D473/34 , C07D473/38 , C07D473/40 , C07D487/04 , Y02A50/30

摘要： The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.

2.

发明授权
GLP-1R modulating compounds 有权

公开(公告)号：US12121511B2

公开(公告)日：2024-10-22

申请号：US17159485

申请日：2021-01-27

申请人： Gilead Sciences, Inc.

发明人： Stephen E. Ammann , Gediminas J. Brizgys , James S. Cassidy , Elbert Chin , Chienhung Chou , Jeromy J. Cottell , Chao-I Hung , Kavoos Kolahdouzan , Daniel G. Shore , Suzanne M. Szewczyk , James G. Taylor , Rhiannon Thomas-Tran , Nathan E. Wright , Zheng-Yu Yang

IPC分类号： A61K31/4184 , A61K31/4192 , A61K31/4196 , A61K31/422 , A61K31/424 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K45/06 , C07D405/10 , C07D405/14 , C07D409/14 , C07D413/10 , C07D471/04 , C07D493/04 , C07D493/10 , C07D498/04

CPC分类号： A61K31/4184 , A61K31/4192 , A61K31/4196 , A61K31/422 , A61K31/424 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K45/06 , C07D405/10 , C07D405/14 , C07D409/14 , C07D413/10 , C07D471/04 , C07D493/04 , C07D493/10 , C07D498/04

摘要： The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition.

3.

发明公开
TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS 审中-公开

公开(公告)号：US20240327396A1

公开(公告)日：2024-10-03

申请号：US18741572

申请日：2024-06-12

申请人： Neuropore Therapies, Inc.

发明人： Emily M. STOCKING , Wolfgang J. WRASIDLO

IPC分类号： C07D413/14 , C07D413/10 , C07D413/12

CPC分类号： C07D413/14 , C07D413/10 , C07D413/12

摘要： The present disclosure relates to tri-substituted aryl and heteroaryl derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for modulating autophagy or preventing, reversing, slowing or inhibiting the PI3K-AKT-MTOR pathway, and methods of treating diseases that are associated with autophagy or the PI3K-AKT-MTOR pathway.

4.

发明授权
Biaryl kinase inhibitors 有权

公开(公告)号：US12065437B2

公开(公告)日：2024-08-20

申请号：US17192985

申请日：2021-03-05

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Guanglin Luo , Carolyn Diane Dzierba , John E. Macor

IPC分类号： C07D471/04 , A61K31/4427 , A61K31/50 , A61P25/28 , C07C233/25 , C07D213/30 , C07D213/34 , C07D213/57 , C07D213/61 , C07D213/64 , C07D213/73 , C07D213/74 , C07D213/75 , C07D213/80 , C07D215/14 , C07D237/08 , C07D239/26 , C07D309/18 , C07D309/22 , C07D401/04 , C07D401/14 , C07D413/10

CPC分类号： C07D471/04 , A61K31/4427 , A61K31/50 , A61P25/28 , C07C233/25 , C07D213/30 , C07D213/34 , C07D213/57 , C07D213/61 , C07D213/64 , C07D213/73 , C07D213/74 , C07D213/75 , C07D213/80 , C07D215/14 , C07D237/08 , C07D239/26 , C07D309/18 , C07D309/22 , C07D401/04 , C07D401/14 , C07D413/10

摘要： The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

5.

发明授权
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use 有权

公开(公告)号：US12059420B2

公开(公告)日：2024-08-13

申请号：US17261954

申请日：2019-07-22

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： James Aaron Balog , Jay A. Markwalder , Weifang Shan , David K. Williams , Susheel Jethanand Nara , Saumya Roy , Soodamani Thangavel , Srinivas Cheruku , Ramesh Kumar Sistla

IPC分类号： A61K31/506 , A61K31/4418 , A61K31/4439 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/519 , A61K31/5377 , A61K39/395 , C07D213/74 , C07D213/75 , C07D401/14 , C07D403/10 , C07D403/14 , C07D405/14 , C07D413/10 , C07D413/14 , C07D417/10 , C07D417/14 , C07D487/04

CPC分类号： A61K31/506 , A61K31/4418 , A61K31/4439 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/519 , A61K31/5377 , A61K39/3955 , C07D213/74 , C07D213/75 , C07D401/14 , C07D403/10 , C07D403/14 , C07D405/14 , C07D413/10 , C07D413/14 , C07D417/10 , C07D417/14 , C07D487/04

摘要： The present invention provides compounds of formula (I): wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.

6.

发明授权
Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors 有权

公开(公告)号：US12053473B2

公开(公告)日：2024-08-06

申请号：US17077232

申请日：2020-10-22

申请人： Boehringer Ingelheim International GmbH

发明人： Dirk Kessler , Christiane Kofink , Matthew Russell Netherton , Juergen Ramharter , Tobias Wunberg

IPC分类号： A61K31/517 , A61K9/20 , A61K31/337 , A61K31/496 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K31/7068 , A61P35/00 , C07D239/94 , C07D401/14 , C07D403/10 , C07D405/12 , C07D405/14 , C07D409/10 , C07D413/10 , C07D487/04

CPC分类号： A61K31/517 , A61K9/2009 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K31/337 , A61K31/496 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K31/7068 , A61P35/00 , C07D239/94 , C07D401/14 , C07D403/10 , C07D405/12 , C07D405/14 , C07D409/10 , C07D413/10 , C07D487/04

摘要： The present invention encompasses compounds of formula (I)

wherein the groups R1 to R7 have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.

7.

发明公开
TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA 审中-公开

公开(公告)号：US20240254079A1

公开(公告)日：2024-08-01

申请号：US18239892

申请日：2023-08-30

申请人： ARCUS BIOSCIENCES, INC.

发明人： Joel Worley BEATTY , Samuel Lawrie DREW , Matthew EPPLIN , Jeremy Thomas Andre FOURNIER , Balint GAL , Tezcan GUNEY , Karl T. HAELSIG , Clayton HARDMAN , Steven Donald JACOB , Jenna Leigh JEFFREY , Jaroslaw KALISIAK , Kenneth Victor LAWSON , Manmohan Reddy LELETI , Erick Allen LINDSEY , Artur Karenovich MAILYAN , Debashis MANDAL , Guillaume MATA , Hyunyoung MOON , Jay Patrick POWERS , Brandon Reid ROSEN , Yongli SU , Anh Thu TRAN , Zhang WANG , Xuelei YAN , Kai YU

IPC分类号： C07C317/32 , A61K31/10 , A61K31/277 , A61K31/343 , A61K31/353 , A61K31/365 , A61K31/381 , A61K31/404 , A61K31/415 , A61K31/416 , A61K31/4174 , A61K31/4192 , A61K31/4196 , A61K31/421 , A61K31/423 , A61K31/426 , A61K31/428 , A61K31/437 , A61K31/44 , A61K31/4412 , A61K31/47 , A61K31/4709 , A61K31/472 , A61K31/4965 , A61K31/50 , A61K31/5025 , A61K31/505 , A61K31/519 , A61K31/538 , A61K39/395 , A61K45/06 , C07C255/53 , C07C317/22 , C07C317/36 , C07D209/34 , C07D211/86 , C07D213/57 , C07D213/71 , C07D213/73 , C07D213/74 , C07D213/84 , C07D215/48 , C07D217/04 , C07D231/12 , C07D231/56 , C07D233/64 , C07D237/20 , C07D239/42 , C07D241/12 , C07D249/06 , C07D249/08 , C07D263/32 , C07D263/57 , C07D265/36 , C07D277/30 , C07D277/56 , C07D277/64 , C07D307/83 , C07D311/22 , C07D333/64 , C07D401/04 , C07D401/10 , C07D409/10 , C07D413/10 , C07D471/04 , C07D487/04

CPC分类号： C07C317/32 , A61K31/10 , A61K31/277 , A61K31/343 , A61K31/353 , A61K31/365 , A61K31/381 , A61K31/404 , A61K31/415 , A61K31/416 , A61K31/4174 , A61K31/4192 , A61K31/4196 , A61K31/421 , A61K31/423 , A61K31/426 , A61K31/428 , A61K31/437 , A61K31/44 , A61K31/4412 , A61K31/47 , A61K31/4709 , A61K31/472 , A61K31/4965 , A61K31/50 , A61K31/5025 , A61K31/505 , A61K31/519 , A61K31/538 , A61K39/3955 , A61K45/06 , C07C255/53 , C07C317/22 , C07C317/36 , C07D209/34 , C07D211/86 , C07D213/57 , C07D213/71 , C07D213/73 , C07D213/74 , C07D213/84 , C07D215/48 , C07D217/04 , C07D231/12 , C07D231/56 , C07D233/64 , C07D237/20 , C07D239/42 , C07D241/12 , C07D249/06 , C07D249/08 , C07D263/32 , C07D263/57 , C07D265/36 , C07D277/30 , C07D277/56 , C07D277/64 , C07D307/83 , C07D311/22 , C07D333/64 , C07D401/04 , C07D401/10 , C07D409/10 , C07D413/10 , C07D471/04 , C07D487/04 , C07C2602/08 , C07C2602/10

摘要： Compounds that inhibit HIF-2α, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2α.

8.

发明授权
Diaryl-azole compound and formulation for controlling harmful organism 有权

公开(公告)号：US12037326B2

公开(公告)日：2024-07-16

申请号：US17500866

申请日：2021-10-13

申请人： Nippon Soda Co., Ltd.

发明人： Keita Sakanishi , Takao Iwasa , Hikaru Aoyama , Norifumi Sakiyama , Daisuke Ushijima , Maki Matsui , Tomomi Kobayashi

IPC分类号： C07D401/14 , A01N43/50 , A01N43/54 , A01N43/56 , A01N43/653 , A61K31/506 , A61P31/10 , A61P31/14 , C07D233/64 , C07D401/04 , C07D403/04 , C07D403/10 , C07D403/14 , C07D413/10

CPC分类号： C07D403/14 , A01N43/50 , A01N43/54 , A01N43/56 , A01N43/653 , A61K31/506 , A61P31/10 , A61P31/14 , C07D233/64 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/10 , C07D413/10

摘要： A compound represented by Formula (I), or a salt thereof:

wherein, R1 represents an unsubstituted or substituted C1-6 alkylthio group, or the like; A1 represents a nitrogen atom or CH; A2 represents a nitrogen atom or CR2; R2 and R3 each independently represents a hydrogen atom, an unsubstituted or substituted C6-10 aryl group, an unsubstituted or substituted 3- to 6-membered heterocyclyl group, or the like; B1 and B2 each independently represents a nitrogen atom or CR5, with the proviso that B1 and B2 do not represent CR5 at the same time, wherein R5 represents a hydrogen atom, an unsubstituted or substituted C1-6 alkyl group, or the like; R4 represents an unsubstituted or substituted C1-6 alkyl group, or the like, and R4 binds to any one of nitrogen atoms forming an imidazole ring or a triazole ring; and Ar represents an unsubstituted or substituted C6-10 aryl group or the like.